

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/808,732	03/14/2001	Richard F. Hammen	" A-69071/RFT	5501	
759	90 08/18/2004	•	EXAM	IINER -	
FLEHR HOHBACH TEST ALBERITTON & HERBERT LLP Suite 3400			THERKORN, ERNEST G.		
Four Embarcade	ero Center		ART UNIT	. PAPER NUMBER	
San Francisco,	CA 94111-4187	•	1723 ·	.,	
			DATE MAILED: 08/18/200	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		09/808,732	HAMMEN ET AL.				
ome Action Cumme	41 <b>y</b>	Examiner	Art Unit				
The MAILING DATE of this or		Ernest G. Therkorn	1723				
Period for Reply	mmunication app	ears on the cover sheet wi	th the correspondence address				
A SHORTENED STATUTORY PER THE MAILING DATE OF THIS COM - Extensions of time may be available under the pafter SIX (6) MONTHS from the mailing date of - If the period for reply specified above is less that - If NO period for reply is specified above, the ma - Failure to reply within the set or extended period - Any reply received by the Office later than three - earned patent term adjustment. See 37 CFR 1.	MMUNICATION.  brovisions of 37 CFR 1.13 this communication.  In thirty (30) days, a reply ximum statutory period w for reply will, by statute, months after the mailing	36(a). In no event, however, may a re within the statutory minimum of thirt vill apply and will expire SIX (6) MON cause the application to become AB	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communic ANDONED (35 U.S.C. & 133).	ation.			
Status							
1) Responsive to communication	n(s) filed on <u>July</u> 2	21, 2004&August 5, 2004.					
2a)⊠ This action is <b>FINAL</b> .	∑ This action is FINAL. 2b)  This action is non-final.						
			ers, prosecution as to the merit	s is			
closed in accordance with the	practice under E	x parte Quayle, 1935 C.D	. 11, 453 O.G. 213.				
Disposition of Claims							
4) Claim(s) <u>1,6,7,12 and 28-36</u> is	s/are pending in t	he application.					
4a) Of the above claim(s)		• •					
5) Claim(s) is/are allowed							
6)⊠ Claim(s) <u>1,6,7,12 and 28-36</u> is	s/are rejected.						
7) Claim(s) is/are objecte		•					
8) Claim(s) are subject to	restriction and/or	election requirement.					
Application Papers							
9)☐ The specification is objected to	by the Examine	r.					
10) The drawing(s) filed on	=		by the Examiner.				
Applicant may not request that a			•				
			s) is objected to. See 37 CFR 1.12				
11)☐ The oath or declaration is obje	cted to by the Ex	aminer. Note the attached	Office Action or form PTO-152	<u>?</u> .			
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a a) All b) Some * c) Non		priority under 35 U.S.C. §	119(a)-(d) or (f).				
1.☐ Certified copies of the p		have been received					
		s have been received in A	oplication No.				
			received in this National Stage				
application from the Inte							
* See the attached detailed Office	e action for a list o	of the certified copies not i	received.				
•••							
Attachment(s)  1)  Notice of References Cited (PTO-892)		, <b>–</b> 1					
<ol> <li>Notice of References Cited (P10-892)</li> <li>Notice of Draftsperson's Patent Drawing Re</li> </ol>	eview (PTO-948)	4) [_] Interview Si Paper No(s	ummary (PTO-413) )/Mail Date				
3) Information Disclosure Statement(s) (PTO- Paper No(s)/Mail Date		5) 🔲 Notice of In	formal Patent Application (PTO-152)				
S. Patent and Trademark Office		6) Other:	_				

Art Unit: 1723

Applicant is advised that should claim 7 be found allowable, claim 28 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 706.03(k).

Claims 35 and 36 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. No support can be found for claims 35 and 36's pore size. Page 14, lines 15-18 of the specification does not appear to be directed to pores.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 29, and 30 are rejected under 35 U.S.C. 102(B) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092). The claims are considered to read on each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092). However, if a difference exists between the claims and each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092), it would reside in optimizing the elements of each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092). It would have been obvious to optimize the elements of each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) to enhance separation.

Claims 1, 29, and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875). At best, the claims differ from each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in reciting the network is permeable. Betz (U.S. Patent No. 5,653,875) (column 16, lines 16-23 and 30-37) discloses that a polysiloxane network coating is permeable to allow access to the particles. It would have been obvious that each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) is permeable because Betz (U.S. Patent No. 5,653,875) (column 16, lines 16-23 and 30-37) discloses that a polysiloxane network coating is permeable to allow access to the particles.

Claim 6 is rejected under 35 U.S.C. 103(a) as being unpatentable over either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) as applied to claims 1, 29, and 30 above, and further in view of Frechet (U.S. Patent No. 5,334,310) and Biebricher (U.S. Patent No. 4,177,038). At best, the claim differs from either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) in implying use of a functional group and reciting use of a tether. Frechet (U.S. Patent No. 5,334,310) (column 7, lines 35-64) discloses that functional groups are essential for ion exchange chromatography, hydrophobic interaction, and reversed phase chromatography and allow use of affinants specific for a single compound. Biebricher (U.S. Patent No. 4,177,038) (column 1, lines 34-40) discloses use of a spacer overcomes steric interference. It would have been obvious to use a functional group in either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) because Frechet (U.S. Patent No. 5,334,310) (column 7, lines 35-64) discloses that functional groups are essential for ion exchange chromatography, hydrophobic interaction, and reversed phase chromatography and allow use of affinants specific for a single compound. It would have been obvious to use a spacer in either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092)

Art Unit: 1723

alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) and Frechet (U.S. Patent No. 5,334,310) because Biebricher (U.S. Patent No. 4,177,038) (column 1, lines 34-40) discloses use of a spacer overcomes steric interference.

Claims 7 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) as applied to claims 1, 29, and 30 above, and further in view of Frechet (U.S. Patent No. 5,334,310) and Snyder, Introduction to Modern Liquid Chromatography, 1979, 276-279. At best, the claims differ from either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) in implying use of a functional group and reciting use of a blocking agent. Frechet (U.S. Patent No. 5,334,310) (column 7, lines 35-64) discloses that functional groups are essential for ion exchange chromatography, hydrophobic interaction, and reversed phase chromatography and allow use of affinants specific for a single compound. Snyder, Introduction to Modern Liquid Chromatography, 1979, 276-279 discloses "capping" ensures optimum surface coverage by organic groups. It would have been obvious to use a functional group in either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) because

Frechet (U.S. Patent No. 5,334,310) (column 7, lines 35-64) discloses that functional groups are essential for ion exchange chromatography, hydrophobic interaction, and reversed phase chromatography and allow use of affinants specific for a single compound. It would have been obvious to use a spacer in either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) and Frechet (U.S. Patent No. 5,334,310) because Snyder, Introduction to Modern Liquid Chromatography, 1979, 276-279 discloses "capping" ensures optimum surface coverage by organic groups.

Claims 31-33 are rejected under 35 U.S.C. 103(a) as being unpatentable over either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) as applied to claims 1, 29, and 30 above, and further in view of Frechet (U.S. Patent No. 5,334,310). At best, the claims differ from either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) in reciting use of a functional group. Frechet (U.S. Patent No. 5,334,310) (column 7, lines 35-64) discloses that functional groups are essential for ion exchange chromatography, hydrophobic interaction, and reversed phase chromatography and allow use of affinants specific for a single compound. It would have been obvious to use a functional group in either Good

Art Unit: 1723

(U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) because Frechet (U.S. Patent No. 5,334,310) (column 7, lines 35-64) discloses that functional groups are essential for ion exchange chromatography, hydrophobic interaction, and reversed phase chromatography and allow use of affinants specific for a single compound.

Claims 12 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) in view of Frechet (U.S. Patent No. 5,334,310) as applied to claims 31-33 above, and further in view of Larson (U.S. Patent No. 5,723,601). At best, the claims differ from either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) in view of Frechet (U.S. Patent No. 5,334,310) in reciting use of an enzyme. Larson (U.S. Patent No. 5,723,601) (column 1, lines 25-28, column 2, lines 47-50, column 4, lines 2-16) discloses that enzymes are desirable functional groups for continuous beds. It would have been obvious to use an enzyme in either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) in view of Frechet (U.S. Patent No. 5,334,310) because Larson (U.S. Patent No. 5,723,601) (column 1, lines 25-28, column 2,

Art Unit: 1723

lines 47-50, column 4, lines 2-16) discloses that enzymes are desirable functional groups for continuous beds.

Claims 35 and 36 are rejected under 35 U.S.C. 103(a) as being unpatentable over either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) as applied to claims 1, 29, and 30 above, and further in view of Frechet (U.S. Patent No. 5,334,310). At best, the claims differ from each of either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) in reciting use of pores greater than 100 nanometers. Frechet (U.S. Patent No. 5,334,310) (column 4, lines 54-68) discloses that large pores greater than 600 nanometers reduce backpressure. It would have been obvious to use pores greater than 100 nanometers in each of either Good (U.S. Patent No. 3,808,125) or Fuller (U.S. Patent No. 3,878,092) alone or each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) in view of Betz (U.S. Patent No. 5,653,875) because Frechet (U.S. Patent No. 5,334,310) (column 4, lines 54-68) discloses that large pores greater than 600 nanometers reduce backpressure.

The remarks urge patentability based upon interstices. However, interstices are disclosed in Fuller (U.S. Patent No. 3,878,092) on column 7, lines 66-67 and Good (U.S. Patent No. 3,808,125) on column 6, line 40. The interstices are shown in each of Good (U.S. Patent No. 3,808,125) and Fuller

Art Unit: 1723

(U.S. Patent No. 3,878,092) Figures 3, 4, 5, and 6 as element 30. Accordingly, the claims are considered to read on each of Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092).

The remarks urge patentability based upon the limitation that the polymer network is permeable to fluids. However, Fuller (U.S. Patent No. 3,878,092) on column 2, lines 40 and 57, column 5, line 3, and column 7, lines 66-67 discloses that his film is highly porous and Good (U.S. Patent No. 3,808,125) on column 6, lines 40 disclose his medium is porous. Accordingly, Good (U.S. Patent No. 3,808,125) and Fuller (U.S. Patent No. 3,878,092) are considered to be permeable.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication should be directed to E. Therkorn at telephone number (571) 272-1149. The official fax number is (703) 872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ernest G. Therkorn Primary Examiner Art Unit 1723

EGT August 17, 2004